Clinical bottom line
Detrusor underactivity (DU) is an underrecognized cause of refractory male lower urinary tract symptoms (LUTS) characterized by impaired bladder contractility leading to incomplete emptying and urinary retention. Novel therapeutic approaches targeting DU remain limited, with current management largely supportive or surgical. Emerging pharmacologic agents and neuromodulation techniques show promise but require further validation. Clinicians should carefully differentiate DU from bladder outlet obstruction (BOO) using urodynamic and non-invasive assessments to guide therapy. The evidence base for novel therapies is evolving, and individualized treatment decisions remain essential.
What the evidence shows
DU is defined by reduced strength and/or duration of detrusor contraction resulting in prolonged or incomplete bladder emptying (Yoshida et al., 2014). It frequently coexists with BOO in men with LUTS, complicating diagnosis and management (Wada et al., 2021). Differentiating DU from BOO is critical because treatments effective for obstruction may worsen symptoms in DU (Rosier et al., 2015).
Recent advances include development of nomograms integrating bladder outlet resistance and contractility to improve diagnostic precision (Rosier et al., 2015). Non-invasive indicators such as uroflowmetry patterns and bladder ultrasound post-void residual volume have been explored to predict DU, but their accuracy remains suboptimal (Wada et al., 2021; unpublished 2024 study).
Therapeutic options for refractory DU are limited. Pharmacologic agents aiming to enhance detrusor contractility, such as parasympathomimetics, have shown inconsistent efficacy and are not widely recommended (Yoshida et al., 2014). Neuromodulation approaches, including sacral nerve stimulation, have demonstrated potential to improve voiding function in small cohorts but lack large-scale randomized data (Rubilotta et al., 2024).
Surgical interventions like bladder outlet reduction or augmentation cystoplasty may be considered in select cases but carry significant risks and variable outcomes (Griebling et al., 2016; Wein et al., 2018). Emerging regenerative therapies and bioengineered bladder constructs remain investigational.
Caveats and uncertainty
The pathophysiology of DU is heterogeneous and incompletely understood, involving myogenic, neurogenic, and age-related factors (Yoshida et al., 2014). This complexity complicates patient stratification and therapeutic targeting. Most studies are small, observational, or retrospective, limiting generalizability.
Non-invasive diagnostic tools lack sensitivity and specificity, and invasive urodynamics remain the gold standard despite being resource-intensive (Wada et al., 2021). The overlap of DU with BOO and other LUTS etiologies challenges clear clinical phenotyping.
Evidence supporting novel pharmacologic or neuromodulation therapies is preliminary, with few randomized controlled trials available. Long-term safety and efficacy data are sparse. Surgical options are associated with morbidity and require careful patient selection.
How this may change practice
Clinicians should maintain a high index of suspicion for DU in men with refractory LUTS, especially when standard treatments for BOO fail. Incorporating urodynamic studies and validated nomograms can improve diagnostic accuracy and guide management.
While no novel therapies have yet achieved widespread adoption, emerging neuromodulation techniques may become viable adjuncts for refractory cases pending further evidence. Pharmacologic agents targeting detrusor contractility warrant cautious use given limited efficacy data.
Multidisciplinary approaches including pelvic floor rehabilitation and careful monitoring of bladder function are advisable. Future integration of non-invasive diagnostics and personalized therapies may enhance outcomes.
Ongoing research into the molecular mechanisms and novel interventions for DU is critical to advance care for this challenging patient population.